SPGL-008

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSPGL-008
Drug Alias NameSPGL008SPGL-008
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-CD276Anti-IL15
TargetsCD276 antigenInterleukin-15
Therapy Area/IndicationsUrinary Bladder NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Sciprogen Bio-Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenzhen Sciprogen Bio-Pharmaceutical Co LtdShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesNorthern Medicine Gu Desheng (Shenyang) Biotechnology Co Ltd
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A